hVIVO PLC HVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBP 0.32
- Day Range
- GBP 0.32–0.32
- 52-Week Range
- GBP 0.17–0.36
- Bid/Ask
- GBP 0.00 / GBP 0.00
- Market Cap
- GBP 219.08 Mil
- Volume/Avg
- 1,454 / 1,476
Key Statistics
- Price/Earnings (Normalized)
- 21.58
- Price/Sales
- 3.43
- Dividend Yield (Trailing)
- 0.73%
- Dividend Yield (Forward)
- 0.73%
- Total Yield
- 0.73%
Company Profile
hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences’ Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 274
- Website
- https://www.hvivo.com
Comparables
Valuation
|
Metric
|
HVO
|
BVXP
|
ABCZF
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.58 | 26.73 | 94.80 |
Price/Book Value | 5.54 | 19.17 | 5.63 |
Price/Sales | 3.43 | 16.39 | 11.32 |
Price/Cash Flow | 14.63 | 24.40 | 56.19 |
Price/Earnings
HVO
BVXP
ABCZF
Financial Strength
|
Metric
|
HVO
|
BVXP
|
ABCZF
|
|---|---|---|---|
Quick Ratio | 1.43 | 6.69 | 0.99 |
Current Ratio | 1.48 | 7.04 | 1.35 |
Interest Coverage | 65.30 | — | 0.93 |
Quick Ratio
HVO
BVXP
ABCZF
Profitability
|
Metric
|
HVO
|
BVXP
|
ABCZF
|
|---|---|---|---|
Return on Assets (Normalized) | 13.83% | 68.76% | 6.16% |
Return on Equity (Normalized) | 34.06% | 77.21% | 8.92% |
Return on Invested Capital (Normalized) | 25.17% | 76.10% | 7.46% |
Return on Assets
HVO
BVXP
ABCZF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Rwlzywzbg | Gcbr | $635.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dfdjvckl | Stnrmm | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tlqdrvgw | Pfzkkq | $114.2 Bil | |||
| Moderna Inc
MRNA
| Pmbvgrcvv | Nqdb | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Ybgtqmtc | Nhmj | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Msbrnmh | Jrcy | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qtbbwyyy | Mzfckxn | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Spsqlpht | Wkjtcz | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Ncjxzsl | Rlnft | $12.8 Bil | |||
| Incyte Corp
INCY
| Dpcjhwf | Dhnrh | $12.2 Bil |